Merck's $1.3B EyeBio investment yields first ophthalmology success

Merck's strategic move to re-enter ophthalmology has begun to show results after its 2024 acquisition of EyeBio.

The company committed $1.3 billion upfront for EyeBio, aiming to broaden its pipeline beyond the oncology flagship Keytruda. The recent milestone marks the first tangible outcome of that investment.

Analysts view the development as a positive signal for Merck's diversification efforts, though the broader impact will depend on subsequent clinical progress.